![Deborah Charych](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: - $ in data 31/08/2026
Dr. Deborah Charych is an Independent Director at Skye Bioscience, Inc. and a Chief Executive Officer, CFO & Secretary at Utter Therapeutics, Inc. She is on the Board of Directors at Skye Bioscience, Inc. Dr. Charych was previously employed as a Chief Technology Officer by Rayzebio, Inc., a Founder by Third Rock Ventures LP, a Director-Preclinical & Translational Research by Nektar Therapeutics, a Director-Biologics Process Development by Five Prime Therapeutics, Inc., and a Co-Founder by Maze Therapeutics, Inc. She received her undergraduate degree from Carnegie Mellon University and a doctorate degree from the University of California, Berkeley.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SKYE BIOSCIENCE, INC. | Direttore/Membro del Consiglio | 14/02/2023 |
| Società | Posizione | Fine |
|---|---|---|
| RAYZEBIO, INC. | Fondatore | 01/09/2022 |
Third Rock Ventures LP
 Third Rock Ventures LP Investment ManagersFinance Acts as Venture Capital Fund | Fondatore | 01/01/2019 |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | 01/01/2018 |
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Fondatore | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 8 |
|---|---|
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
Third Rock Ventures LP
Third Rock Ventures LP Investment ManagersFinance Acts as Venture Capital Fund | Finance |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Skye Bioscience, Inc.
 Skye Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets cannabinoid derivatives to treat ophthalmic disorders | Health Technology |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine for cardiovascular, renal and metabolic diseases | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
